Hologic, Inc. (HOLX) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Hologic, Inc. (NASDAQ:HOLX) have been given a consensus rating of “Buy” by the sixteen analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $48.79.
A number of research firms recently weighed in on HOLX. Needham & Company LLC reissued a “buy” rating and set a $50.00 target price (up from $48.00) on shares of Hologic in a research report on Tuesday, January 9th. BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a research report on Saturday. Cowen raised Hologic to a “buy” rating and set a $52.00 target price on the stock in a research report on Wednesday, December 20th. Bank of America raised Hologic from a “neutral” rating to a “buy” rating and set a $50.00 target price on the stock in a research report on Thursday, January 4th. Finally, Evercore ISI began coverage on Hologic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 target price on the stock.
In other Hologic news, VP Karleen Marie Oberton sold 1,256 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $39.29, for a total transaction of $49,348.24. Following the completion of the transaction, the vice president now owns 9,406 shares in the company, valued at $369,561.74. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,099 shares of company stock valued at $487,223. Corporate insiders own 0.79% of the company’s stock.
Shares of Hologic (NASDAQ HOLX) opened at $43.71 on Tuesday. The stock has a market capitalization of $12,050.13, a PE ratio of 16.56, a PEG ratio of 2.09 and a beta of 0.95. Hologic has a 1 year low of $35.76 and a 1 year high of $46.80. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. During the same period last year, the business posted $0.52 earnings per share. The firm’s revenue was up 10.5% compared to the same quarter last year. sell-side analysts predict that Hologic will post 2.15 EPS for the current year.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.